| Summary of making decisions regarding the allocation of resources and to assess performance |
The criteria applied to identify the operating segments are consistent with the information reviewed by the Chief Executive Officer (the Group’s “Chief Operating Decision Maker”) in making decisions regarding the allocation of resources and to assess performance.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As at and for the year ended December 31, 2021 |
|
(EUR thousand) |
|
Biopharmaceutical
and Diagnostic
Solutions |
|
|
Engineering |
|
|
Total
segments |
|
|
Adjustments,
eliminations
and
unallocated
items |
|
|
Consolidated |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External Customers |
|
|
694,038 |
|
|
|
149,882 |
|
|
|
843,920 |
|
|
|
— |
|
|
|
843,920 |
|
Inter-Segment |
|
|
1,134 |
|
|
|
68,979 |
|
|
|
70,113 |
|
|
|
(70,113 |
) |
|
|
— |
|
Total Revenues |
|
|
695,172 |
|
|
|
218,861 |
|
|
|
914,033 |
|
|
|
(70,113 |
) |
|
|
843,920 |
|
Cost of Sales |
|
|
465,304 |
|
|
|
176,604 |
|
|
|
641,908 |
|
|
|
(63,393 |
) |
|
|
578,515 |
|
Gross Profit |
|
|
229,868 |
|
|
|
42,257 |
|
|
|
272,125 |
|
|
|
(6,720 |
) |
|
|
265,405 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other operating income |
|
|
9,386 |
|
|
|
— |
|
|
|
9,386 |
|
|
|
— |
|
|
|
9,386 |
|
Selling and Marketing expenses |
|
|
7,736 |
|
|
|
3,196 |
|
|
|
10,932 |
|
|
|
9,516 |
|
|
|
20,448 |
|
Research and Development expenses |
|
|
23,467 |
|
|
|
4,263 |
|
|
|
27,730 |
|
|
|
1,886 |
|
|
|
29,616 |
|
General and Administrative expenses |
|
|
58,996 |
|
|
|
11,898 |
|
|
|
70,894 |
|
|
|
(8,392 |
) |
|
|
62,502 |
|
Operating Profit |
|
|
149,055 |
|
|
|
22,900 |
|
|
|
171,955 |
|
|
|
(9,730 |
) |
|
|
162,225 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
|
885,733 |
|
|
|
253,767 |
|
|
|
1,139,500 |
|
|
|
279,342 |
|
|
|
1,418,842 |
|
Total liabilities |
|
|
335,919 |
|
|
|
163,661 |
|
|
|
499,580 |
|
|
|
77,603 |
|
|
|
577,183 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As at and for the year ended December 31, 2020 |
|
(EUR thousand) |
|
Biopharmaceutical
and Diagnostic
Solutions |
|
|
Engineering |
|
|
Total
segments |
|
|
Adjustments,
eliminations
and
unallocated
items |
|
|
Consolidated |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External Customers |
|
|
564,931 |
|
|
|
97,106 |
|
|
|
662,037 |
|
|
|
— |
|
|
|
662,037 |
|
Inter-Segment |
|
|
1,096 |
|
|
|
56,327 |
|
|
|
57,423 |
|
|
|
(57,423 |
) |
|
|
— |
|
Total Revenues |
|
|
566,027 |
|
|
|
153,433 |
|
|
|
719,460 |
|
|
|
(57,423 |
) |
|
|
662,037 |
|
Cost of Sales |
|
|
398,411 |
|
|
|
121,332 |
|
|
|
519,743 |
|
|
|
(51,882 |
) |
|
|
467,861 |
|
Gross Profit |
|
|
167,616 |
|
|
|
32,101 |
|
|
|
199,717 |
|
|
|
(5,541 |
) |
|
|
194,176 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other operating income |
|
|
5,193 |
|
|
|
31 |
|
|
|
5,224 |
|
|
|
7 |
|
|
|
5,230 |
|
Selling and Marketing expenses |
|
|
9,762 |
|
|
|
2,842 |
|
|
|
12,604 |
|
|
|
7,440 |
|
|
|
20,044 |
|
Research and Development expenses |
|
|
12,080 |
|
|
|
3,056 |
|
|
|
15,136 |
|
|
|
2,254 |
|
|
|
17,390 |
|
General and Administrative expenses |
|
|
48,324 |
|
|
|
9,641 |
|
|
|
57,965 |
|
|
|
899 |
|
|
|
58,863 |
|
Operating Profit |
|
|
102,643 |
|
|
|
16,593 |
|
|
|
119,236 |
|
|
|
(16,127 |
) |
|
|
103,109 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
|
776,832 |
|
|
|
188,751 |
|
|
|
965,583 |
|
|
|
2,396 |
|
|
|
967,979 |
|
Total liabilities |
|
|
330,624 |
|
|
|
109,325 |
|
|
|
439,949 |
|
|
|
217,890 |
|
|
|
657,839 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2019 |
|
(EUR thousand) |
|
Biopharmaceutical
and Diagnostic
Solutions |
|
|
Engineering |
|
|
Total
segments |
|
|
Adjustments,
eliminations
and
unallocated
items |
|
|
Consolidated |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External Customers |
|
|
455,041 |
|
|
|
81,498 |
|
|
|
536,539 |
|
|
|
— |
|
|
|
536,539 |
|
Inter-Segment |
|
|
881 |
|
|
|
45,625 |
|
|
|
46,506 |
|
|
|
(46,506 |
) |
|
|
— |
|
Total Revenues |
|
|
455,922 |
|
|
|
127,123 |
|
|
|
583,045 |
|
|
|
(46,506 |
) |
|
|
536,539 |
|
Cost of Sales |
|
|
333,539 |
|
|
|
104,291 |
|
|
|
437,830 |
|
|
|
(39,312 |
) |
|
|
398,518 |
|
Gross Profit |
|
|
122,383 |
|
|
|
22,832 |
|
|
|
145,215 |
|
|
|
(7,194 |
) |
|
|
138,021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other operating income |
|
|
8,737 |
|
|
|
0 |
|
|
|
8,737 |
|
|
|
0 |
|
|
|
8,737 |
|
Selling and Marketing expenses |
|
|
13,776 |
|
|
|
3,113 |
|
|
|
16,889 |
|
|
|
9,255 |
|
|
|
26,144 |
|
Research and Development expenses |
|
|
5,442 |
|
|
|
1,549 |
|
|
|
6,991 |
|
|
|
835 |
|
|
|
7,826 |
|
General and Administrative expenses |
|
|
43,167 |
|
|
|
8,157 |
|
|
|
51,324 |
|
|
|
(756 |
) |
|
|
50,568 |
|
Operating Profit |
|
|
68,735 |
|
|
|
10,013 |
|
|
|
78,748 |
|
|
|
(16,528 |
) |
|
|
62,220 |
|
|